TABLE 1.
Demographics, clinical characteristics, and CSF data for the study cohort, stratified by biological criteria (SYN+AD vs. SYN−AD).
| Variable | SYN+AD group (n=22) | SYN−AD group (n=38) | p value | |
|---|---|---|---|---|
| Clinical Disorder, n (%) | DLB | 11 (50) | 12 (32) | 0.25 a |
| PDD | 11 (50) | 26 (68) | ||
| Sex, n Male (%) | 17 (77) | 27 (71) | 0.82 a | |
| Education, y (SD) | 14.7 (2.4) | 16.1 (2.3) | 0.03 b | |
| Age, y (SD) | 70.8 (7.8) | 68.2 (6.5) | 0.25 b | |
| Disease duration, y (SD) | 6.8 (4.9) | 9.4 (6.6) | 0.17 b | |
| Cognitive symptom duration, y (SD) | 2.2 (3.5) | 2.9 (2.3) | 0.17 b | |
| Neuropsychological & Neurological Examination Scores | ||||
| n | 21 | 38 | p value | |
| MMSE, max=30 (SD) | 24.7 (5.9) | 26.5 (2.9) | 0.47 c | |
| F letter fluency, words/min (SD) | 8.9 (5.1) | 13.2 (5.5) | 0.11 c | |
| Animal semantic fluency, words/min (SD) | 12.1 (5.4) | 16 (7.3) | 0.04 c | |
| BNT, max=30 (SD) | 24.3 (4.5) | 26.9 (4.0) | 0.03 b | |
| MoCA Delayed Word Recall, max=5 (SD) | 1.2 (1.9) | 2.0 (1.8) | 0.35 c | |
| MDS-UPDRS Part III total, max=132 (SD) | 32.5 (11.1) | 34.9 (9.8) | 0.48 c | |
| MDS-UPDRS Part III rigidity, max=4 (SD) | 1.1 (1.4) | 1.1 (1.1) | 0.96 c | |
| MDS-UPDRS Part III tremor at rest, max=4 (SD) | 0.1 (0.4) | 0.3 (0.6) | 0.43 c | |
| MDS-UPDRS Part III hand action/postural tremor left + right, max=8 (SD) | 1.2 (1.4) | 1.8 (1.3) | 0.37 c | |
| CSF AD biomarker levels | ||||
| n | 18 | 35 | p value | |
| Time between CSF and speech (months) | 31.0 (26.7) | 18.2 (14.6) | 0.06 c | |
| CSF p-Tau, pg/mL | 20.1 (11.7) | 19.5 (9.0) | 0.86 c | |
| CSF t-Tau, pg/mL | 47.3 (21.2) | 55.4 (32.6) | 0.28 c | |
| CSF Aβ, pg/mL | 158.5 (47.8) | 296.9 (69.1) | - | |
| Active medications | ||||
| n | 22 | 38 | p value | |
| Dopaminergic therapy = yes (%) | 11 (50) | 25 (66) | 0.35 | |
| Cholinesterase inhibitor = yes (%) | 7 (32) | 5 (13) | 0.16 | |
| Anti-depressants/ neuroleptics = yes (%) | 4 (18) | 7 (18) | 1.00 | |
| Clinical Syndrome, n (%) | DLB | 11 (50) | 12 (32) | 0.25 a |
| PDD | 11 (50) | 26 (68) | ||
| Sex, n Male (%) | 17 (77) | 27 (71) | 0.82 a | |
| Education, y (SD) | 14.7 (2.4) | 16.1 (2.3) | 0.03 b | |
| Age, y (SD) | 70.8 (7.8) | 68.2 (6.5) | 0.25 b | |
| Disease duration, y (SD) | 6.8 (4.9) | 9.4 (6.6) | 0.17 b | |
| Cognitive symptom duration, y (SD) | 2.2 (3.5) | 2.9 (2.3) | 0.17 b | |
| Neuropsychological & Neurological Examination Scores | ||||
| n | 21 | 38 | p value | |
| MMSE max=30 (SD) | 24.7 (5.9) | 26.5 (2.9) | 0.47 b | |
| F letter fluency words/min (SD) | 8.9 (5.1) | 13.2 (5.5) | 0.11 c | |
| BNT max=30 (SD) | 24.3 (4.5) | 26.9 (4.0) | 0.03 b | |
| MoCA Delayed Word Recall max=5 (SD) | 1.2 (1.9) | 2.0 (1.8) | 0.35 c | |
| MDS-UPDRS Part III max=132 (SD) | 32.5 (11.1) | 34.9 (9.8) | 0.48 c | |
| CSF AD biomarker levels | ||||
| n | 19 | 33 | p value | |
| Time between CSF and speech (months) | 31.0 (26.7) | 18.2 (14.6) | 0.060 c | |
| CSF p-Tau, pg/mL | 20.1 (11.7) | 19.5 (9.0) | 0.86 c | |
| CSF t-Tau, pg/mL | 47.3 (21.2) | 55.4 (32.6) | 0.28 c | |
| CSF Aβ, pg/mL | 158.5 (47.8) | 296.9 (69.1) | - | |
p value reflects χ2 test estimate.
p value reflects H test estimate.
p value reflects t test estimate.
Abbreviations: SYN+AD= LBD patients with autopsy/CSF evidence of significant AD co-pathology; SYN-AD= LBD patients without AD co-pathology; DLB=dementia with Lewy Bodies; PDD=Parkinson’s disease dementia; disease duration=interval from disease onset to speech collection date; Cognitive symptom duration=interval from dementia onset to speech sampling date; MMSE = Mini Mental State Examination; BNT = Boston Naming Test; MoCA = Montreal Cognitive Assessment; MDS-UPDRS Part III= The MDS-sponsored Revision of the Unified Parkinson’s Disease Rating Scale motor examination.